SILO PHARMA, INC. Proceeds from Sale of Equity Method Investments
SILO PHARMA, INC. (SILO) reported Proceeds from Sale of Equity Method Investments of $66.71 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2023-03-24
- SILO PHARMA, INC. proceeds from sale of equity method investments for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. proceeds from sale of equity method investments for the quarter ending 2022-09-30 was $0.00.
- SILO PHARMA, INC. proceeds from sale of equity method investments for the quarter ending 2021-12-31 was $284.46K.
- SILO PHARMA, INC. proceeds from sale of equity method investments for the quarter ending 2019-12-31 was $0.00.
- SILO PHARMA, INC. proceeds from sale of equity method investments for fiscal 2022 was $66.71K, a 99.05% decline from fiscal 2021.
- SILO PHARMA, INC. proceeds from sale of equity method investments for fiscal 2021 was $7.02M.
- SILO PHARMA, INC. proceeds from sale of equity method investments for fiscal 2019 was $191.94K.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $66.71K 10-K · filed 2023-03-24 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $66.71K 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $66.71K 10-Q · filed 2022-08-01 | |||
| 2021-12-31 | $284.46K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $7.02M 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $6.74M 10-Q · filed 2022-11-10 | |||
| 2019-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | $132.95K derived: sum of 2 quarters · filed 2021-05-17 | $191.94K 10-K/A · filed 2021-05-17 | |
| 2019-09-30 | $132.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $191.94K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $58.99K 10-Q · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |